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Introduction: As a consequence of sepsis and
intensive care, considerable proportions of patients but
also of their spouses develop a post-traumatic stress
disorder (PTSD). However, only a very small number
receive psychotherapeutic treatment. Internet-based
cognitive–behavioural writing therapy (IB-CBWT) has
proven to be an effective treatment option for PTSD.
It seems to fit the specific needs of this cohort and to
overcome treatment barriers. Aim of the REPAIR trial
is to examine the efficacy, safety and applicability of
IB-CBWT for PTSD in patients and their spouses after
intensive care for sepsis.
Methods and analysis: Participants will be assigned
randomly either to a treatment or a wait-list (WL)
control group. The treatment group receives IB-CBWT
for PTSD, actively involving the partners of the
participants. IB-CBWT will be guided by a therapist and
comprises two written assignments per week over a
5 week period. After completing the assignments, the
participants obtain individual responses from the
therapist. Participants of the WL control group will
receive treatment after a waiting period of 5 weeks.
The primary outcome is PTSD symptom severity in
self-rated PTSD Checklist for Diagnostic and Statistical
Manual Fifth Edition at the end of treatment and waiting
time, respectively. Secondary outcomes are remission
of PTSD, depression, anxiety, and somatisation
measured by the Brief Symptom Inventory-18, marital
satisfaction measured by the Relationship Assessment
Scale, health-related quality of life measured by the EQ-
5D-5L, and the feasibility of IB-CBWT for this cohort
(ie, dropout rate). Statistical analysis will be performed
according to the intent-to-treat principle.
Ethics and dissemination: The study is conducted
according to the principles of Good Clinical Practice
and has been approved by the ethics committee of the
Friedrich-Schiller University Jena, Germany. Results
will be disseminated at scientific conferences,
published in peer-reviewed journals, and provided to
consumers of healthcare.
Trial registration number: Pre-results,
DRKS00010676.
INTRODUCTION
Psychopathological reactions, that is, acute
stress disorder (International Classiﬁcation of
Diseases 10th Revision: F43.0) and post-
traumatic stress disorder (PTSD; F43.1), are
common consequences of life-threatening
events such as sepsis and negatively affect
patients’ long-term functioning and quality
of life.1–4 Critical illness can also be a trau-
matic and stressful experience for family
members as a result of uncertainty and the
fear of the patient’s physical disability or
death. Diagnostic and Statistical Manual Fifth
Edition (DSM-5)5 explicitly deﬁned the diag-
nostic criteria of a traumatic event as an
exposure to actual death or serious injury
experienced in person or which has
occurred to a close family member. Family
Strengths and limitations of this study
▪ This randomised-controlled trial will provide new
evidence concerning the treatment of post-
traumatic stress disorder (PTSD) after intensive
care for sepsis in patients and their spouses.
▪ For the first time also the spouses of patients
with PTSD will be involved in their partners’
internet-based cognitive–behavioural writing
therapy.
▪ Intervention effects will be compared against a
wait-list control group.
▪ It is not possible to ensure a complete blinding
of patients and therapists.
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members, particularly spouses, who care for the critically
ill patient during the time of intensive care, are there-
fore a vulnerable cohort.6–8 In a recent study, up to 69%
of the patients, who had survived sepsis and 62% of the
spouses of sepsis survivors suffered from clinically rele-
vant PTSD symptoms.9 It has been further shown that
both physical and mental health of patients and their
spouses are interrelated. More speciﬁcally, results of a
dyadic analysis indicated that the mental quality of life
of a person (patient or spouse) is negatively impacted
by post-traumatic stress symptoms of the respective
partner. Furthermore, it has been shown that PTSD
symptoms of the patient who survived sepsis are a signiﬁ-
cant predictor of PTSD symptoms of the respective
spouse.10 Based on these results, it has been concluded
that couples react as a dyadic system with interdepend-
ent emotional responses to critical illness. Thus, the
inclusion of spouses in the treatment of mental long-
term consequences of critical illness appears to be inevit-
able.9 However, patients suffering from PTSD after crit-
ical illness are often untreated or undertreated hereof.
Accordingly, Mehlhorn et al11 suggest in their review of
interventions for the postintensive care syndrome, that
“postintensive care patients may beneﬁt from interven-
tions like trauma-focused cognitive–behavioural therapy
[…] but often they do not have access to those interven-
tions”. (p. 1268)
With regard to the treatment of PTSD, several
evidence-based interventions exist. There is striking evi-
dence for the efﬁcacy of trauma-focused cognitive–
behavioural therapy with large effect sizes (standardised
mean difference=1.62; 95% CI (1.21 to 2.03) in a
meta-analysis of 28 studies) compared against wait-list
(WL) control.12 Nevertheless, only a minority of indivi-
duals suffering from PTSD seeks psychological treatment
due to different barriers (eg, fear of stigmatisation,
embarrassment, lack of availability of specialised thera-
pists). In recent years, internet-based interventions based
on CBT techniques have overcome these face-to-face
treatment barriers by treating mobility-impaired patients,
being independent in space and time as well as easily
accessible and due to visual anonymity being low-
threshold.13–15 The internet-based approach is usually
based on a manualised, therapist-assisted treatment
which is operationalised via written assignments. In
general, treatment as well as the diagnostic screenings
(before and after the treatment) are conducted without
any face-to-face contact in a secure web portal.13 16 17
Meta-analytic evidence has proven the efﬁcacy of
internet-based cognitive–behavioural writing therapy
(IB-CBWT) to be large (Hedges′ g=0.95; 95% CI (0.46 to
1.43); 8 studies) in PTSD symptom reduction compared
to WL control.15
Up to now, IB-CBWT has not been considered as a
treatment approach for PTSD after critical illness and
intensive care. Moreover, therapeutic approaches for
PTSD that include spouses in addition to the patients
are very scarce.
Objectives
Primary aims of the REPAIR trial are to investigate the
efﬁcacy, safety and applicability of IB-CBWT for post-
traumatic stress after intensive care for sepsis in patients
and their spouses compared to a WL control group and
to assess maintenance of possible treatment gains at 3, 6
and 12 months post-treatment. Second, the study aims at
examining dyadic concordance in treatment effects, that
is, indirect effects of the treatment in the respective
spouse of the participant of the treatment. Third, the
inﬂuence of dyadic coping on the treatment effects will
be explored.
METHODS AND ANALYSIS
Study design and setting
REPAIR is a randomised-controlled, parallel group,
superiority trial. The current study will be conducted at
the Jena University Hospital, recruiting participants
from German speaking countries (eg, Germany, Austria
and Switzerland) at least 1 month after discharge from
the intensive care unit (ICU). Participants will be con-
tacted via telephone for initial screening and via inter-
net for delivering the treatment and conducting
assessments.
Eligibility criteria
We will include adult (18+ years) patients after intensive
care (>5 days) for sepsis18 and their spouses (married or
cohabited) who are ﬂuent in written German. A
patient–spouse dyad will be included if at least one of
them (patient or spouse or both) scores above the
PCL-5 cut-off (score ≥33)19 for a presumptive PTSD
diagnosis. PTSD should be based on a trauma, which is
associated with the critical illness and/or ICU stay.
Patients will be excluded, if they do not have a spouse.
According to the German clinical guideline on the treat-
ment of PTSD20 acute psychosis and suicidal ideation
will be criteria for exclusion. Furthermore, the use of
neuroleptics, or an ongoing psychotherapeutic treat-
ment elsewhere will be reasons for exclusion.
Procedures
Recruitment
Since the treatment is delivered internet-based, German
speaking patients/spouses could participate from all
over the world. For recruitment, we follow a multipartite
strategy. First, all persons, that is, patients or spouses,
who request free of charge advice from the German
Sepsis Aid’s National Helpline (http://www.sepsis-hilfe.
org) or had requested advice in the past 2 years
(altogether about 600 requests), will be contacted and
informed about the study. Second, patients of the
Mid-German Sepsis Cohort (MSC; trial registration:
German Clinical Trials Register, no. DRKS00010050)
who are positively screened for PTSD at one of the MSC
study assessments will be informed about the study. The
MSC aims at following-up about 1000 patients after
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sepsis per year, of whom we expect about 20% to have
PCL scores ≥33 points at least at one follow-up assess-
ment. Third, participants will be recruited via advertise-
ments in health journals and distribution of information
brochures in hospitals and rehabilitation centres. In a
ﬁrst telephone contact, participants will be screened for
eligibility by using the Life Event Checklist for DSM-5
(LEC 5)21 and the PTSD checklist for DSM-5 (PCL-5).19
Written informed consent will be obtained by the
patients and their spouses (see ﬁgure 1). One signed
version of the informed consent will be sent back to the
study centre. After that, an appointment for a second
telephone interview will be terminated. In this second
telephone contact, patients and their spouses will com-
plete the Clinician-Administered PTSD Scale for DSM-5
(CAPS-5)22 and the Structured Clinical Interview for
DSM-IV (SCID-I)23 conducted by a trained psychologist.
Medical data will be assessed (eg, length of intensive
care and (if) length of mechanical ventilation, time
since ICU discharge).
Randomisation
All eligible patient–spouse dyads consenting to participa-
tion will be randomly assigned to either IB-CBWT or to
a WL control group (allocation ratio 1:1) with the
patient–spouse dyad being the unit of randomisation.
Randomisation will be conducted using a central
internet-based registration system provided by the
Center for Clinical Studies of the Jena University
Hospital. This system automatically randomises patients
and generates a message noting the assigned treatment.
The underlying randomisation list will be developed by
an independent biometrician using a computer-based
algorithm. Allocation will be concealed and stratiﬁed by
the occurrence of PTSD symptoms within the dyads of
sepsis survivor and the spouse: strata 1—both, sepsis sur-
vivor and spouse with PTSD; strata 2—sepsis survivor
with PTSD/spouse without, and strata 3—spouse with
PTSD/sepsis survivor without.
Baseline assessment (t0)
Before the start of the treatment participants, that is,
patients and their spouses, will be asked to complete the
following questionnaires: PTSD checklist for DSM-5
(PCL-5),19 Brief Symptom Inventory (BSI),24 Resilience
Scale (RS13),25 Proactive Coping Inventory (PCI),26
Multidimensional Fatigue Inventory (MFI),27 EQ-5D-5L
health questionnaire,28 Index for Measuring Limitations
of Social Participation (IMET),29 Dyadic Coping
Inventory (DCI),30 Relationship Assessment Scale
(RAS)31 and Internet Literacy Questionnaire (ILQ; sub-
scale technical expertise).32 Additionally, Posttraumatic
Cognitions Inventory (PTCI)33 will be assessed only in
participants with PCL scores ≥33 points (table 1).
Intervention phase
Internet-based writing therapy
Patients and/or spouses with PCL scores ≥33 points,
who are allocated to the treatment condition, will par-
ticipate in an IB-CBWT. They will be asked to complete
two 50 min writing assignments per week over a 5-week
period (10 essays in total). The therapy consists of three
treatment modules (table 2): (1) resource-oriented bio-
graphical reconstruction (three essays), (2) in sensu
trauma exposure sessions (four essays) and (3) cognitive
reconstruction (three essays).
Integrated in the third module, the respective partner
of the treated participant diagnosed with PTSD receives
instructions to write a supportive letter to him/her.
Here, the respective partner should announce acknowl-
edgement for the participant as well as his/her strengths
and the shared future. Partners without clinically rele-
vant PTSD symptoms will also receive access to an indi-
vidual web portal where they complete the assessments
and write the supportive letter. They further receive psy-
choeducational information about mental health pro-
blems after traumatic events (ie, explanation of PTSD
symptoms and treatment options).
Figure 1 Study flow chart. CAPS/SCID-I, Clinician-
Administered PTSD Scale for DSM-5/Structured Clinical
Interview for DSM-IV DSM, Diagnostic and Statistical Manual;
PTSD, post-traumatic stress disorder.
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At the beginning of each writing assignment, partici-
pants propose individual timetables as to when they plan
to write. After completion of each assignment, therapists
provide individual feedback and further writing instruc-
tions within one workday. Important aspects of this feed-
back are acknowledgement of the participant’s courage
to disclose and describe their traumatic experiences,
reinforcement of the participant’s work on the essays,
positive feedback and motivation and frequent summar-
ies and encouragement of participants to voice their
questions and doubts. Study participants will complete
writing assignments through a secure web portal, ensur-
ing that all correspondence is conﬁdential and
encrypted. Communication between participants and
their therapist will occur asynchronously.
Every participant (patient and spouse) will receive
access to a private, secure user account within the web
portal. During treatment, all communication will be con-
ducted within this account. Additionally, the therapist
accounts are located in the web portal being secure and
only accessible for the therapists. A database located at
the server of the Jena University Hospital is connected
with the web-portal, saving data using anonymous codes
meeting the highest security standards.
Therapists
Therapists will be licensed clinical psychologists with pre-
vious experience in IB-CBWT. They will receive specia-
lised training in the administration of the treatment and
will be supervised continuously throughout the trial.
Participants will be consecutively assigned to the thera-
pists. When both, patient and spouse, have clinically rele-
vant PTSD symptoms, they will have different therapists.
Measurement during the course of treatment
During treatment, that is, after assignments 3, 7 and 10,
the Multiperspective Assessment of General Change
Mechanisms in Psychotherapy (SEWIP),34 measuring
resource activation, problem actuation, mastery, clariﬁca-
tion of meaning, emotional bond and agreement on
Table 1 Schedule of the assessments
Study period
Enrolment Allocation Intervention Follow-up















PCL-5 x x x x x x x x
LEC-5 x
BSI x x x x x x x
RAS x x x x x x x
IMET x x x x x
RS-13 x x x x x
EQ-5D-5L x x x x x
MFI x x x x x
DCI x x x x x
PTCI x x x x x
PCI x x x x x
SEWIP* x x x
Adverse events x x x
*SEWIP is only applied to patients with PCL scores ≥33.
BSI, Brief Symptom Inventory; CAPS-5, Clinician-Administered PTSD Scale for DSM-5; DCI, Dyadic Coping Inventory; EQ-5D-5L, health
questionnaire of the EuroQol group; IB-CBWT, Internet-based cognitive–behavioural writing therapy; ILQ, Internet Literacy Questionnaire;
IMET, Index for Measuring Limitations of Social Participation; LEC-5, Life Event Checklist for DSM-5; MFI, Multidimensional Fatigue Inventory;
PCI, Proactive Coping Inventory; PCL-5, Post-traumatic stress disorder checklist; PTCI, Post-traumatic Cognitions Inventory; RAS,
Relationship Assessment Scale; RS13, Resilience Scale; S3, after treatment session 3; S7, after treatment session 7; SCID-I, Structured
Clinical Interview for DSM-IV; SEWIP, Multiperspective Assessment of General Change Mechanisms in Psychotherapy; t0, Baseline, before
start of treatment/waiting; t1, after end of treatment/waiting; t2, 3 months after end of treatment; t3, 6 months after end of treatment; t4,
12 months after end of treatment, (t2–t4 only for intervention group); tx, time of enrolment.
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collaboration, will be applied to participants of the
IB-CBWT group. Additionally, PCL-5, BSI and RAS will be
administered during therapy (after assignments 3 and 7).
Measurement at the end of treatment/waiting (t1)
At the end of treatment or waiting time, respectively, the
following measures will be applied to the participants:
PCL-5, BSI, RS13, PCI, MFI, EQ-5D-5L, IMET, DCI and
RAS. Again, PTCI will be assessed only in participants
with PCL scores ≥33 points (table 1). Additionally, parti-
cipants will be interviewed by using the Clinician-
Administered PTSD Scale for DSM-5 (CAPS-5).
Wait-list control group
Treatment effects will be compared against a WL control
group to allow for the provision of care (if delayed) to
all trial participants. After 5 weeks of waiting (duration
of treatment), participants allocated to the WL control
group will receive IB-CBWT. During and after this
delayed application of IB-CBWT, the same measures as
in the treatment condition will be assessed. However,
these participants will not receive a supportive letter
from their spouses. This will allow for evaluating the
effect ascribed to the supportive letter.
Follow-up phase
Participants assigned to the treatment group will be fol-
lowed up 3, 6 and 12 months after treatment, respect-
ively. Participants assigned to the WL control group will
be followed up 3 months after treatment. Outcome mea-
sures will be assessed again (table 1).
Discontinuation
If a participant meets any of the following criteria, the
study intervention will be discontinued: withdrawal of
consent to receive the study intervention, emergence of
an adverse event (suicidal ideation, severe symptom
increase) or start of psychotherapy elsewhere. The par-
ticipant will be invited to continue completing the
planned assessments. If participants withdraw consent to
study participation, they will not be contacted for assess-
ments in the future. Participants have the right to initi-
ate deletion of their study data. If a participant does not
make use of this right, all data will be included in the
analyses.
If either the spouse or patient drops out of the study
for any reason, the other participant will be allowed to
continue with the intervention and study participation.
Outcome measures
Primary outcome
Primary outcome is the change in PTSD symptom sever-
ity score from baseline to 5 weeks after randomisation
(t1; at the end of treatment/waiting time) measured via
the PTSD Checklist (PCL-5) covering the four DSM-5
clusters.19
Secondary outcomes
Secondary outcomes will be remission at t1 and the per-
centage of participants leaving the study early (during
treatment phase) due to any reason (until t1).
Furthermore, anxiety, depression and somatisation
(Brief Symptom Inventory-1824), marital satisfaction
(Relationship Assessment Scale31) and health-related
quality of life (EQ-5D-5L28) all measured as summary
scores at t1 and at follow-up (t2–t4: 3, 6, and 12 months).
Other measures
Additionally, we will assess dyadic coping with stress in
the patient–spouse dyads using the Dyadic Coping
Table 2 Framework of the 10 writing assignments delivered during IB-CBWT after sepsis for patients and their spouses
Session number Session goals Suggested structure Suggested tools
1–3 Resource-oriented biographical
reconstruction.
Explaining the reason of the
reconstruction.
Provide a list of life-events.
Provide a summary and give
individual feedback.
Provide list of possible important
personal life events
“What problems did you have and
how do you solve it?”
4–7 In sensu exposure.
Detailed description of the trauma
with all sensations.
Explain the need of exposure.
Explain how to describe the
trauma in a written way.
Provide a summary and give
individual feedback.
Provide a list of questions due to
the traumatic event and the
sensations.
Text of partner








Provide a list of questions due to
the goals of the letter.
8–10 Cognitive reconstruction: writing a
letter to an imaginary friend.




Provide a summary and give
individual feedback.
Provide a list of questions due to
the goals of the letter.
eg, “Has something positive
resulted from the events?”
IB-CBWT, Internet-based cognitive–behavioural writing therapy.
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Inventory,30 coping with stress on an individual level
using the Proaactive Coping Inventory,26 social participa-
tion using the Index for Measuring Limitations of Social
Participation,29 resilience (deﬁned as the capacity to
withstand life stressors and to thrive and make meaning
from challenges35) using the Resilience Scale-13,25
fatigue using the Multidimensional Fatigue Inventory27
and post-traumatic cognitions using the Posttraumatic
Cognitions Inventory.33 All of these measures will be
applied at baseline (t0), at the end of treatment/waiting
time (t1) and at follow-up (t2–t4). During (S3, S7) and
at the end of treatment (t1), we will assess common
therapeutic factors in patients with PCL scores ≥33
using the Multiperspective Assessment of General
Change Mechanisms in Psychotherapy.34
Sample size estimation
The sample size calculation is based on the parametric
evaluation of a two-group comparison using Students’
t-test, though a more complex statistical model will be
used as the primary test. To detect large effect sizes as
revealed by a meta-analysis,15 that is, effects of Cohen’s
d=0.95, while requiring α=0.05 (two-sided) while aiming
at a comparison-wise power of 1—β=0.9 (a higher power
was chosen to address the problem that a more complex
statistical analysis will be used), a sample size of
n=2×34=68 patient–spouse dyads is necessary for the
intent-to-treat (ITT) analysis. Dropout rates in IB-CBWT
are encouragingly low; in a previous study with older
adults (65+ years, comparable in age to the population of
the proposed study), 89% of the participants completed
every step of treatment.16 However, additional dropouts
in a sample of sepsis survivors may be due to medical
reasons, that is, health impairment or sudden death.
Thus, we decided to increase the power by assuming a
dropout rate of 30%, so that altogether 98 dyads have to
be randomised to either IB-CBWTor WL control group.
Methods against bias
Selection bias will be minimised by random and con-
cealed central allocation of the patient–spouse dyads to
treatment and control group using a centralised ran-
domisation by the Center for Clinical Studies of the
Jena University Hospital. However, performance bias
might not be ruled out because blinding of patients/
spouses could not be realised due to intervention
characteristics. Similarly, therapists cannot be fully
blinded to group assignment since participants receiving
treatment the ﬁrst weeks of recruitment must have been
automatically allocated to the treatment group.
Treatments will be carefully manualised and predeﬁned
in terms of the content and number of sessions. To
assure treatment ﬁdelity, verbatim scripts of the corres-
pondence between participants and therapists will be
reviewed. Treatment ﬁdelity checks will be performed
based on a random selection of 30% of treatment ses-
sions. Data will be analysed using an ITT approach. To
ensure data quality, diagnoses will be made on the basis
of a validated clinical interview conducted by a clinically
experienced and trained psychologist. Questionnaires
that will be used in the proposed study have been
proven to be psychometrically sound instruments. To
reduce the risk of sampling bias and to assure external
validity, we will use a multipartite recruitment strategy
and apply less restrictive eligibility criteria.
Statistical analyses
The primary end point of the efﬁcacy assessment
(PCL-5 change score at the end of the treatment, t1, ie,
∼6 weeks after randomisation; relative to the randomisa-
tion t0) will be compared between both groups
(ie, experimental group and WL control group). The
null hypothesis μEXP=μWL, which implies that the PCL-5
change scores are identical in expectation, will be tested
against the (two-sided) alternative hypothesis that there
will be a difference between the groups (μEXP ≠ μWL).
The conﬁrmatory analysis will be performed in the ITT
population. These hypotheses will be tested using a
general linear model for the primary outcome and the
group factor adjusted for PCL-5 at baseline (t0) with
generalised estimating equations component to address
the possible intradyad clustering. The null hypothesis
will be rejected when the two-sided p value for the
group variable is equal to or less than the two-sided sig-
niﬁcance level α=0.05. The average mean difference in
the PCL-5 change scores at t1 is assumed to be clinically
relevant when the mean PCL-5 score is more than 10
points lower for the experimental group than for the
WL control group.19
We will address missing values by replacing all missing
change scores with the worst change observed.
Furthermore, we will explore the potential impact of
dropouts (ie, missingness not completely at random) on
the results in sensitivity analyses that will be outlined in
the statistical analysis plan (SAP).
Additionally, there will be sensitivity analyses, for
example, in the per-protocol (PP) population or strati-
ﬁed by patient and spouse. All additional analyses and
the analyses of secondary end points will be carried out
exploratively, that is, without adjustment for multiplicity.
We will use adequate standard descriptive and inferen-
tial statistical techniques that are described in detail
in the SAP. For the third explorative objective—
dyadic interference in mental health—we will use a
longitudinal Actor-Partner-Interdependence Model. To
examine the impact of dyadic coping on treatment
effects, we will extend the previously applied regression
models.
Data collection and management
Data collection
Relevant data will be collected via telephone and using
questionnaires delivered via the web-portal.
Telephonically assessed data will be documented in
writing and transferred to the study management soft-
ware ‘OpenClinica’. Data assessed by using standardised
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questionnaires within the web-portal, will be collected
via a secure network (HTTPS) using input forms in the
web browser. Data will be saved by using anonymised
codes on a server of the Jena University Hospital ensur-
ing highest safety standards.
Data management
Data management will be conducted by using the study
management software ‘OpenClinica’ meeting common
regulatory requirements (GCP, 21CFRPart11). To ensure
a pseudonymised data analysis, every participant will
receive a distinct ID. Data will be checked regularly for
accuracy, implausible or missing data will be enquired in
the study centre.
Study monitoring
The current study will be monitored by an independent
data manager of the Centre for Clinical Studies of the
Jena University Hospital including periodic inspections
of the completeness and correctness of study documents
and study data.
Premature termination of the study
Reasons for a premature termination of the study will be
unjustiﬁable risks of continuation, new scientiﬁc ﬁndings
during study duration or inadequate recruiting rate.
Decision about discontinuation will be taken jointly by
the principal investigators, the study biometrician and
the Data Safety and Monitoring Board.
Reporting of adverse events
Assessment of safety will include recording any adverse
effects during the treatment period by asking partici-
pants for experienced adverse events at the end of the
treatment. In addition, during treatment participants
are provided a telephone contact for emergency cases.
In such a case, adverse events will be documented by
the study team.
Ethical considerations and dissemination
Informed consent
All eligible participants will be informed orally by a
trained clinical psychologist about aims, content, proced-
ure and length of the study; and about any potential
risks and advantages in a true manner. After providing
the opportunity to ask questions, written consent will be
obtained by sending the informed consent document
back to the study centre. Participants further receive a
brochure with detailed information about the study.
Participation is voluntary at any time. Participants will be
informed about the voluntariness of study participation
and the opportunity to interrupt or prematurely termin-
ate study participation without giving reasons.
Ethics review
The study has been approved by the ethics committee of
the Friedrich-Schiller University Jena, Germany (number
4777-04/16, 11 May 2016). The trial is registered in the
German Clinical Trials Register (DRKS); number
DRKS00010676. Modiﬁcations in the study protocol
will be communicated to the ethics committee as well as
the DRKS.
Access to data
Principal investigators and the study statistician will have
access to the ﬁnal data set. To ensure conﬁdentiality,
data dispersed to project team members will be blinded
of any identifying participant information.
Dissemination
Results of this study will be presented at scientiﬁc confer-
ences and published in peer-reviewed journals.
Furthermore, we will disseminate results and conclusions
to consumers of healthcare. The study will be implemen-
ted and reported in line with the CONSORT statement.
Authorship is granted to authors who make important
contributions to the creation of the ﬁnal publication.
DISCUSSION
This study aims to provide new evidence of treatment
approaches particularly designed for patients after crit-
ical illness such as sepsis. The current study also involves
the spouse of the affected patient since critical illness
has consequences not only for the patient itself, but also
for his/her spouse who shares concerns, sorrows and
problems.
The limitation of this study is that the intervention
effects will be compared against a WL control group
which might overestimate the efﬁcacy of the treatment
to a certain degree.36 This will be taken into account
in the interpretation of the results. Moreover, evidence-
based treatment approaches of in post-ICU patients
are rare.11 This argues against an active control condi-
tion. Alternatively, psychological treatment placebo
faces the problem that the development of such a
control condition in PTSD trials ‘is very difﬁcult, if not
impossible’.12
Moreover, performance bias will possibly inﬂuence the
effects since participants cannot be blinded because
they are aware of their group allocation. Additionally,
therapists will not be blinded to group assignment.
However, manualisation of the treatment and treatment
ﬁdelity checks will counter the risk of bias.
Despite these limitations, this is the ﬁrst randomised
controlled trial to assess the efﬁcacy, safety and ap-
plicability of an IB-CBWT after sepsis in patients and
their spouses. Given the sparse number of existing treat-
ment approaches for this group of patients IB-CBWT
might be a valuable addition in the treatment of PTSD
after sepsis. The results of this study will hopefully
improve healthcare after sepsis for patients and their
spouses. Given the efﬁcacy, safety and applicability of
this approach, the treatment could be easily transferred
to other languages and thereby disseminated
internationally.
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